AbbVie Inc.

AbbVie, Inc.'s next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, AbbVie, Inc. has 1.77B shares outstanding.

As of June 30, 2026, AbbVie, Inc. maintains a current ratio of 0.81, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -1,202.82, indicating conservative leverage, while an interest coverage ratio of 8.48 demonstrates adequate ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on invested capital (ROIC) comes in at 18.11 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.63, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.45, useful for judging operating efficiency across full business cycles. The company generates approximately 997,470.19 in revenue per employee across its workforce of 56,500.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.64 indicates how many times AbbVie, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, AbbVie, Inc. recorded 2.09B in income tax expense. That works out to an effective tax rate of 27.39, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 7.61B, leaving 5.52B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, AbbVie, Inc. generated 56.36B in revenue and converted that into 5.52B in net income, yielding earnings per share of 3.12. EBITDA reached 21.65B, while operating income came in at 19.13B.

As of June 30, 2026, AbbVie, Inc. holds 5.75B in cash and equivalents against 61.99B in total debt, resulting in a net debt position of 56.24B. Total book value stands at -5.19B, with working capital of -6.98B providing operational flexibility.

AbbVie, Inc. produced 17.07B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.14B in capital expenditures, free cash flow totaled 15.94B - equivalent to 9.02 per share.

Over the twelve months ended June 30, 2026, AbbVie, Inc. posted a gross margin of 71.48, reflecting its pricing power and cost economics. The operating margin of 33.94 and net profit margin of 9.80 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, AbbVie, Inc. paid dividends of 5.93 per share. The dividend payout ratio of 189.47 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.